Lisanti Capital Growth LLC Purchases New Shares in Alphatec Holdings, Inc. $ATEC

Lisanti Capital Growth LLC acquired a new position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) during the third quarter, Holdings Channel reports. The fund acquired 227,287 shares of the medical technology company’s stock, valued at approximately $3,305,000.

Several other institutional investors and hedge funds also recently made changes to their positions in ATEC. Osterweis Capital Management Inc. bought a new position in shares of Alphatec during the second quarter valued at about $37,000. Nisa Investment Advisors LLC increased its stake in Alphatec by 22.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock valued at $63,000 after buying an additional 1,045 shares during the last quarter. R Squared Ltd bought a new position in shares of Alphatec during the 2nd quarter worth approximately $114,000. State of Alaska Department of Revenue purchased a new position in shares of Alphatec in the 3rd quarter worth approximately $120,000. Finally, State of Wyoming bought a new position in shares of Alphatec in the second quarter valued at approximately $124,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Trading Down 0.1%

Shares of Alphatec stock opened at $14.83 on Friday. The stock has a market capitalization of $2.20 billion, a P/E ratio of -14.26 and a beta of 1.01. Alphatec Holdings, Inc. has a 52-week low of $8.81 and a 52-week high of $23.29. The company has a debt-to-equity ratio of 43.02, a quick ratio of 1.24 and a current ratio of 1.99. The stock’s 50-day simple moving average is $19.65 and its 200 day simple moving average is $16.88.

Alphatec (NASDAQ:ATEC) last posted its earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.09. The business had revenue of $196.50 million during the quarter, compared to analysts’ expectations of $182.78 million. During the same quarter in the previous year, the business earned ($0.28) EPS. Alphatec’s revenue for the quarter was up 30.4% on a year-over-year basis. As a group, research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on ATEC. Piper Sandler reiterated an “overweight” rating and set a $25.00 price target (up from $20.00) on shares of Alphatec in a report on Friday, October 31st. Loop Capital set a $25.00 target price on Alphatec in a research report on Wednesday, December 10th. Wall Street Zen raised shares of Alphatec from a “hold” rating to a “buy” rating in a report on Saturday. Barclays raised their price objective on shares of Alphatec from $23.00 to $27.00 and gave the stock an “overweight” rating in a report on Wednesday, January 7th. Finally, TD Cowen reiterated a “buy” rating on shares of Alphatec in a research note on Tuesday. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Alphatec currently has an average rating of “Moderate Buy” and an average target price of $22.82.

Insider Buying and Selling

In related news, Director David R. Pelizzon sold 250,000 shares of Alphatec stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $20.62, for a total value of $5,155,000.00. Following the completion of the transaction, the director directly owned 10,895,045 shares in the company, valued at approximately $224,655,827.90. The trade was a 2.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Jennifer N. Pritzker sold 250,000 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $20.62, for a total value of $5,155,000.00. Following the sale, the insider owned 10,895,045 shares in the company, valued at approximately $224,655,827.90. This represents a 2.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 3,233,342 shares of company stock valued at $66,688,781. Company insiders own 20.90% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.